OakChart

Rani Therapeutics Holdings Inc

RANIHealthcare·Biotechnology·USA·Micro·NASD·Nov 11 • 3:49 PM ET

0.5687+0.0086 (1.54%)
2026-11-11 21:50 CET
Market cap
64.65 USD m
Revenue, TTM
6.58 USD m
Net income, TTM
-32.46 USD m
Free cash flow, TTM
- USD m
EPS diluted, TTM
-0.19
P/E
-
Compare

Price

RANI against its 20, 50 and 200-day averages
2050200beat
0.600.801.001.203.2M6.3MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26RANIclose 0.5720-day 0.6050-day 0.72200-day 0.900.5752w low

73.6% under the 52-week high of 2.16 on 13 Nov 2025. 52-week low 0.51 on 5 Nov 2026. Last 15 sessions, 23.5% high to low

Volume 0.55× normal · the line is the 50-bar volume average

Profile

RANI
52-week range, 4% of the way up
0.512.15

Rani Therapeutics Holdings, Inc. engages in the operation of a clinical stage bio-therapeutics company. The company was founded by Mir Imran on February 21, 2012 and is headquartered in San Jose, CA.

Employees71
IPOJul 30, 2021
Beta0.68
ATR, 14d0.04
Rel volume0.55
Short float9.34%
Insider own23.76%
Inst own28.85%

Snapshot

6 groups

Valuation

Index-
Market Cap79.28M
Enterprise Value44.32M
Income-32.46M
Sales6.58M
Book/sh0.29
Cash/sh0.33
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees71
IPOJul 30, 2021

Ratios

P/E-
Forward P/E-
PEG-
P/S12.05
P/B1.93
P/C1.74
P/FCF-
EV/EBITDA-
EV/Sales6.74
Quick Ratio5.26
Current Ratio5.26
Debt/Eq0.09
LT Debt/Eq0.06
Option/ShortYes / Yes

Earnings

EPS (ttm)-0.19
EPS next Y-0.19
EPS next Q-0.05
EPS this Y62.04%
EPS next Y-10.69%
EPS next 5Y28.28%
EPS past 3/5Y29.57% 11.92%
Sales past 3/5Y- 28.73%
EPS Y/Y TTM76.29%
Sales Y/Y TTM448.67%
EPS Q/Q66.70%
Sales Q/Q-
EarningsNov 09 AMC
EPS/Sales Surpr.15.79% 33.41%

Ownership

Insider Own23.76%
Insider Trans0.19%
Inst Own28.85%
Inst Trans3.12%
ROA-103.59%
ROE-248.60%
ROIC-90.35%
Gross Margin90.17%
Oper. Margin-530.44%
Profit Margin-493.00%
SMA20-4.47%
SMA50-20.93%
SMA200-36.81%
Trades-

Technical

Shs Outstand115.49M
Shs Float88.00M
Short Float9.34%
Short Ratio14.12
Short Interest8.22M
52W High2.15 -73.61%
52W Low0.51 11.51%
Volatility6.76% 6.95%
ATR (14)0.04
RSI (14)39.39
Beta0.68
Rel Volume0.55
Avg Volume582.06K
Volume312,507

Performance

Perf Week-0.72%
Perf Month-22.44%
Perf Quarter-28.73%
Perf Half Y-45.84%
Perf YTD-57.87%
Perf Year-70.69%
Perf 3Y-71.28%
Perf 5Y-98.01%
Perf 10Y-
Recom1.00
Target Price7.20
Prev Close0.56
Price0.57
Change %1.54%

Analyst ratings

latest 9 of 9
DateActionAnalystRating changeTargetImplied
Aug 18, 2026InitiatedCChardan Capital MarketsBuy$6+955.0%
Apr 14, 2026InitiatedLLake StreetBuy$9+1,482.6%
Aug 02, 2024InitiatedOOppenheimerOutperform$17+2,889.3%
Jun 14, 2024InitiatedMMaxim GroupBuy$15+2,537.6%
Jun 13, 2024InitiatedRRodman & RenshawBuy$10+1,658.4%
Apr 17, 2023ResumedBBTIG ResearchBuy$24+4,120.2%
Oct 11, 2022InitiatedUUBSBuy$15+2,537.6%
Jul 27, 2022InitiatedHH.C. WainwrightBuy$22+3,768.5%
Jun 13, 2022InitiatedWWedbushOutperform$28+4,823.5%

Peers

Mkt cap
TickerCompanyMkt cap
ORMPOramed Pharmaceuticals Inc170.96M
ENTXEntera Bio Ltd562.47M
VANIVivani Medical Inc101.48M
LPCNLipocine Inc17.55M
HALOHalozyme Therapeutics Inc11.60B
PYPDPolypid Ltd132.23M
VKTXViking Therapeutics Inc3.65B
NTRBNutriband Inc71.36M
AQSTAquestive Therapeutics Inc448.08M
NVONovo Nordisk ADR137.37B

Insider trading

3 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
IMRAN MIR ADirectorJul 21 '26Buy0.6936,00024,8402,119,334Jul 23 04:10 PM
Javadi AlirezaChief Technical OfficerMar 27 '26Sale0.783863019,689Jul 21 07:24 PM
Imran TalatChief Executive OfficerJul 17 '26Buy0.7235,00025,193469,736Jul 21 06:29 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
VXFVanguard Extended Market Index ETFAUM: 30.47B
IBBQInvesco Nasdaq Biotechnology ETFAUM: 130.27M
BIBProShares Ultra Nasdaq Biotechnology 2X SharesAUM: 107.35M

News

latest 14 of 200
  • Rani Therapeutics Reports Third Quarter 2026 Financial Results; Provides Corporate Update (GlobeNewswire) +5.03%
  • Rani Therapeutics to Participate in the Chardan Healthcare Conference (GlobeNewswire) -8.59%
  • Rani Therapeutics Announces Acceptance into U.S. FDA's Emerging Technology Program (ETP) (GlobeNewswire)
  • Rani Therapeutics to Participate in Upcoming September Conferences (GlobeNewswire)
  • Rani Therapeutics Reports Second Quarter 2026 Financial Results; Provides Corporate Update (GlobeNewswire)
  • Rani Therapeutics to Participate in the Canaccord Genuity 46th Annual Growth Conference (GlobeNewswire)
  • Rani Therapeutics Appoints Michelle Gilson to Board of Directors (GlobeNewswire)
  • Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
  • Rani Therapeutics Announces Positive Initial Phase 1a Data for RT-114 for the Treatment of Obesity, with Oral Bioavailability Exceeding Matched Subcutaneous Dosing (GlobeNewswire)
  • Rani Therapeutics Announces Research and Development Collaboration with PegBio to Expand Obesity Pipeline Across Multiple Novel Candidates (GlobeNewswire)
  • Rani Therapeutics Appoints Nicholas Maestas as Chief Financial Officer (GlobeNewswire)
  • Rani Therapeutics Holdings, Inc. Announces Pricing of $20.0 Million Registered Direct Offering of Class A Common Stock Priced At-The-Market Under Nasdaq Rules (GlobeNewswire) -12.10%
  • Rani Therapeutics Reports First Quarter 2026 Financial Results; Provides Corporate Update; Announces CFO Transition (GlobeNewswire) -9.97%
  • Rani Therapeutics to Participate in the H.C. Wainwright Annual BioConnect Investor Conference (GlobeNewswire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
No quarterly earnings.

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
No annual earnings.

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
No estimate revisions.

Estimate history

EPS, annual-1.347-0.846-0.423-1.284-1.332-1.054-0.449-0.1875
Period2019202020212022202320242025TTM
EPS, quarterly-0.235-0.274-0.217-0.183-0.117-0.07-0.039-0.04-0.039
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual0.9790.4622.717001.0281.6336.58
Period2019202020212022202320242025TTM
Sales, quarterly01.0280.172001.4611.7081.7081.707
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual19.73919.73919.71225.29526.03633.4397.622115.491
Period2019202020212022202320242025MRQ
Shares, quarterly29.80733.4333.5739.23747.94197.62299.813112.499115.491
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Total Revenue6.581.631.030.000.002.720.460.98
Cost of Goods Sold Incl. D&A0.650.901.030.821.31---
Gross Profit5.940.730.00-0.82-1.31---
Selling, General and Administrative Excl. Other40.8639.0449.6065.2862.1453.8216.4227.48
Research and Development21.1120.2026.6839.6236.6126.4812.0424.58
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-34.92-38.31-49.60-66.10-63.45-51.60-16.54-27.07
Interest Expense0.492.895.035.081.070.470.120.01
Unusual Expense0.580.583.710.000.001.070.06-0.07
Net Income Before Taxes-34.32-40.95-56.58-67.88-63.27-53.05-16.67-26.59
Income Taxes0.000.000.000.000.070.040.040.00
Consolidated Net Income-34.32-40.95-56.58-67.88-63.34-53.09-16.70-26.59
Net Income From Continuing Operations-32.46-29.67-30.02-33.97-30.59-8.33-16.70-26.59
Net Income-32.46-29.67-30.02-33.97-30.59-8.33-16.70-26.59
EPS (Recurring)-0.16-0.44-0.96-1.33-1.28-0.38-0.84-1.35
EPS (Basic, Before Extraordinaries)-0.19-0.45-1.05-1.33-1.28-0.42-0.85-1.35
EPS (Diluted)-0.19-0.45-1.05-1.33-1.28-0.42-0.85-1.35
EBITDA-34.28-37.41-48.57-65.28-62.14-51.10-15.96-26.50
Non-Operating Income (Expense)1.670.831.763.301.250.090.060.42
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense8.9211.8016.0319.0112.4716.49--
Price To Sales Ratio23.9154.6837.95--118.62--
Gross Margin90.1744.890.00-----
Operating Margin-530.44-2,345.99-4,824.90---1,899.12-3,580.95-2,764.56
Net Margin-493.00-1,817.09-2,920.04---306.62-3,615.37-2,715.73
Shares Outstanding115.4997.6233.4326.0425.3019.7119.7419.74
Market Capitalization64.6564.6545.6485.92145.85322.29348.11-

Income statement, quarterly

No statement data.

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Cash & Short Term Investments49.9128.1449.0498.98117.4573.0616.54
Short Term Receivables2.160.630.200.000.001.720.25
Inventories0.000.000.000.000.000.000.00
Other Current Assets1.250.981.311.642.140.170.16
Total Current Assets53.3229.7450.55100.62119.5974.9416.94
Net Property, Plant & Equipment5.056.646.827.104.614.474.45
Total Investments and Advances0.000.000.000.000.000.000.00
Long-Term Note Receivable-----0.001.62
Intangible Assets---0.000.000.000.00
Other Assets0.250.250.550.300.000.000.00
Total Assets58.6236.6357.92108.03124.2179.4223.02
Short Term Debt Incl. Current Port. of LT Debt1.5916.465.621.010.001.360.00
Accounts Payable0.311.360.651.461.080.540.20
Other Current Liabilities10.772.071.732.351.563.413.30
Total Current Liabilities12.6719.897.994.822.645.313.50
Long Term Debt2.7313.2524.4829.210.00187.13115.50
Provision for Risks Charges0.000.000.000.000.000.320.66
Other Liabilities1.710.000.000.000.000.000.00
Total Liabilities17.1133.1432.4734.022.64192.75119.66
Non-Equity Reserves0.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.00
Common Equity33.011.9912.8736.8547.41-113.34-96.64
Total Shareholders Equity33.011.9912.8736.8547.41-113.34-96.64
Accumulated Minority Interest8.501.5012.5837.1574.160.000.00
Total Equity41.513.4925.4474.00121.57-113.34-96.64
Total Liabilities & Stockholders Equity58.6236.6357.92108.03124.2179.4223.02
Book Value Per Share0.340.060.491.462.41-5.74-4.90
Tangible Book Value Per Share0.340.060.491.462.41-5.74-4.90
Full-Time Employees71105140163114--
Price to Book Ratio1.9013.094.833.466.806.78-
Return on Assets-62.30-63.50-40.94-26.34-8.18-32.61-
Return on Equity-169.55-404.07-136.64-72.60---
Return on Invested Capital-83.02-196.94-90.95-46.30-17.57-22.64-140.90
Quick Ratio4.211.506.3320.9045.3014.124.84
Current Ratio4.211.506.3320.9045.3014.124.84

Cash flow, annual

No statement data.

Balance sheet, quarterly

No statement data.

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-8.81-8.42-8.02-9.07-7.91-11.22
Depreciation0.120.150.160.190.220.24
Other Funds (Non Cash)2.552.632.323.212.893.97
Funds from Operations-6.13-5.63-5.54-5.68-4.80-7.01
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-1.63-3.39-0.965.97-0.261.22
Cash from Operating Activities-7.76-9.03-6.500.29-5.06-5.80
Capital Expenditures-0.18-0.03-0.010.000.00-0.04
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments7.04-14.52-2.44-30.970.005.75
Purchase of Investments-15.05-34.48-23.43-30.970.000.00
Sale Or Maturity of Investments22.0919.9521.000.000.005.75
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities6.86-14.56-2.45-30.970.005.71
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock-0.3418.820.0154.342.753.95
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock-0.3418.820.0154.342.753.95
Proceedsfrom Stock Options-0.3418.750.0052.670.000.00
Issuance or Reduction of Debt, Net0.000.000.00-9.47-3.75-3.75
Change in Long Term Debt0.000.000.00-9.47-3.75-3.75
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.00-9.47-3.75-3.75
Net Financing Active Other Cash Flow-0.01-0.01-0.03-0.02-0.01-0.01
Other Financing Activities Uses-0.01-0.01-0.03-0.02-0.01-0.01
Cash from Financing Activities-0.3518.81-0.0344.85-1.010.19
Net Change in Cash-1.25-4.78-8.9714.17-6.070.10
Free Cash Flow-7.94-9.06-6.510.29-5.06-5.83

Revenue breakdown

Pharmaceutical Preparations2024: 1.03M 2025: 1.63M
United States2024: 1.03M 2025: 1.63M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
No short interest data.

Option chain

expiry -
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-0910-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-098-KCurrent report2026-11-09SEC
2026-09-294Statement of changes in beneficial ownership of securities2026-09-27SEC
2026-09-294Statement of changes in beneficial ownership of securities2026-09-27SEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-1310-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-138-KCurrent report2026-08-13SEC
2026-08-044Statement of changes in beneficial ownership of securities2026-08-03SEC
2026-08-043Initial statement of beneficial ownership of securities2026-08-01SEC
2026-08-048-KCurrent report2026-08-01SEC
2026-07-31SCHEDULE 13G/ASEC
2026-07-234Statement of changes in beneficial ownership of securities2026-07-21SEC
2026-07-214Statement of changes in beneficial ownership of securities2026-03-27SEC
2026-07-214Statement of changes in beneficial ownership of securities2026-07-17SEC
2026-07-214Statement of changes in beneficial ownership of securities2026-07-17SEC
2026-07-214Statement of changes in beneficial ownership of securities2024-12-27SEC
2026-07-15S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-07-083Initial statement of beneficial ownership of securities2026-06-29SEC
2026-06-308-KCurrent report2026-06-24SEC
2026-06-054Statement of changes in beneficial ownership of securities2026-06-03SEC
2026-06-054Statement of changes in beneficial ownership of securities2026-06-03SEC
2026-06-054Statement of changes in beneficial ownership of securities2026-06-03SEC
2026-06-014Statement of changes in beneficial ownership of securities2026-05-28SEC
2026-06-014Statement of changes in beneficial ownership of securities2026-05-28SEC
2026-06-014Statement of changes in beneficial ownership of securities2026-05-28SEC
2026-06-014Statement of changes in beneficial ownership of securities2026-05-28SEC
2026-06-014Statement of changes in beneficial ownership of securities2026-05-28SEC
2026-06-014Statement of changes in beneficial ownership of securities2026-05-28SEC
2026-05-298-KCurrent report2026-05-28SEC
2026-05-28SCHEDULE 13D/ASEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-0750.03K200
2026-060000
2026-050000
2026-040000
2026-03003011
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
Samsara BioCapital, LLC9.23%
RA CAPITAL MANAGEMENT, L.P.7.56%
AWM Investment Company, Inc.6.67%
VANGUARD CAPITAL MANAGEMENT LLC4.06%
Longaeva Partners L.P.2.07%
Polar Asset Management Partners Inc.2.06%
Siren, L.L.C.1.78%
HEIGHTS CAPITAL MANAGEMENT, INC0.83%
GEODE CAPITAL MANAGEMENT, LLC0.80%
CITADEL ADVISORS LLC0.57%

Funds

Fund% owned
VANGUARD TOTAL STOCK MARKET INDEX FUND3.24%
VANGUARD EXTENDED MARKET INDEX FUND0.74%
Fidelity Extended Market Index Fund0.35%
Fidelity Total Market Index Fund0.12%
Ultra-Small Company Market Fund0.10%
Fidelity Series Total Market Index Fund0.10%
VANGUARD BALANCED INDEX FUND0.04%
VANGUARD INSTITUTIONAL TOTAL STOCK MARKET INDEX FUND0.03%
Victory Extended Market Index Fund0.01%
Invesco Nasdaq Biotechnology ETF0.01%

OakChart. RANI. Cached 15 minutes.

Some panels did not load: si, ea, fc, oc, dv.